|
Synonyms: Fibronum | L19TNF-alpha
Compound class:
Antibody
Comment: Onfekafusp alfa (Fibromun; L19-TNF) is a trimeric homodimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF [1]. LIke bifikafusp alfa, Fibromun targets the TNF to the tumour microenvironment via L19 binding to the angiogenesis-associated isoform of fibronectin (specifically the extradomain B or EDB). Fibromun is being investigated as an immuno-oncology therapeutic. It is one of a growing number of so-called 'immunocytokines' entering clinical development.
|
| No information available. |
Summary of Clinical Use  |
| A combination of fibronum with the similarly designed L19-IL2 diabody bifikafusp alfa is in Phase 3 clinical trial NCT02938299 for malignamt melanoma (Phase 2 results published in [2]). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02938299 | Neoadjuvant L19IL2/L19TNF- Pivotal Study | Phase 3 Interventional | Philogen S.p.A. | ||
